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http://dx.doi.org/10.1016/j.pedneo.2Background: Community-acquired pneumonia (CAP) remains a significant cause of childhood
morbidity worldwide. We analyzed the etiologies and the clinical characteristics of children
who died from CAP. This study aimed at early identification of the poor prognostic factors in
order to improve the efficiency of pneumonia management and prevent deaths.
Methods: A retrospective chart review was performed for children younger than 18 years
admitted to Shin Kong Wu Ho-Su Memorial Hospital between September 1992 and August
2010 with a diagnosis of pneumonia on admission. Twenty-one patients who died with the diag-
nosis of pneumonia and its complications were included in the study, along with 63 age- and
year-matched survival controls.
Results: Twelve patients (57.1%) were younger than 2 years. Gram-negative bacteria (7
patients) were the most frequently identified pathogen, followed by Mycoplasma pneumoniae
(6 patients). Four of these six M. pneumoniae infected patients were co-infected with other
pathogens. Among the clinical characteristics, fatal CAP was associated mainly with initial
presentations of anemia, lymphopenia, thrombocytopenia, bandemia, hyponatremia, sepsis,
meningitis, metabolic acidosis, disseminated intravenous coagulopathy, and underlying
congenital diseases. In multivariate logistic regression analysis, metabolic acidosis (odds
ratio Z 8.50; 95% confidence interval Z 2.82e25.60; p < 0.001) was a prognostic risk factor
for fatality.
Conclusion: For patients with CAP, blood gas should be included in the routine blood test on
admission. Once the initial blood test associated with the aforementioned poor prognosticof Pediatrics, Shin Kong Wu Ho-Su Memorial Hospital, 95, Wenchang Road, Shihlin District, Taipei 111,
m.tw (T.-C. Sung).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
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Fatal community-acquired pneumonia: 18 years of study 23factors has been identified, an immediate treatment including Gram-negative bacilli antibi-
otics should be started aggressively in order to prevent deaths.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Community-acquired pneumonia (CAP) is one of the most
prevalent and serious infections in children and is associ-
ated with a high mortality rate. Pneumonia is estimated to
cause approximately 3 million deaths, or an estimated 29%
of all deaths, among children younger than 5 years world-
wide.1 In Taiwan, CAP represents the fifth leading cause of
death in children.2 Despite advances in antimicrobial
therapy, the mortality rate among hospitalized patients is
still high, ranging from 2% to 30%.3 Clinical response during
the first 2e3 days of treatment appears to predict
outcome.3 Many studies have attempted to create a clinical
prediction rule for detecting CAP in the emergency room.4
This study retrospectively reviewed the medical charts of
children who died from CAP in a medical center between
September 1992 and August 2010. The pathogens of fatal
CAP, patient characteristics, and presenting symptoms
were examined. An age- and year-matched control group
was also studied. This study aimed to detect those high-risk
patients who required emergent clinical intervention
earlier, thereby minimizing the incidence of mortality.
2. Methods
A retrospective chart review of 3308 pediatric patients
admitted to Shin Kong Wu Ho-Su Memorial Hospital from
September 1992 to August 2010 with a diagnosis of pneu-
monia was performed, and cases of fatality were further
analyzed. Inclusion criteria included age less than 18 years,
symptom of cough, and pulmonary infiltration on chest X-
ray. Patients admitted with a diagnosis other than pneu-
monia but who died from pneumonia during hospitalization
were excluded. Twenty-one patients who died from pneu-
monia during this time period were included in the study.
Sixty-three age-matched CAP patients admitted to the
same hospital in the same time period were randomly
selected for the control group. They were separated into
three time periods: September 1992 to August 1998,
September 1998 to August 2004, and September 2004 to
August 2010.
2.1. Microbiology
The blood, sputum, and pleural effusion (if fluid was ob-
tained) were all smeared for Gram staining and incubated.
The enzyme-linked immunosorbent assay (ELISA) test
produced by Savyon Diagnostics (Almere, The Netherlands)
was used to detect antibodies against Mycoplasma pneu-
moniae. The pathogenwas considered definitive if there was
a positive culture in blood or pleural effusion, or a positiveM.
pneumoniae immunoglobulin M antibody (>20 BU/mL), ora four-fold increase in M. pneumoniae immunoglobulin
G antibody two weeks after the acute infection, or cold
agglutinin titers>1:64. Pneumococcal antigen was detected
in urine and pleural effusion using the Binax NOW rapid
immunochromatographic membrane test.
2.2. Definitions
Clinical features and blood test were obtained on admis-
sion, and were defined as fever (>38.0C, rectal), hypo-
thermia(<35C, rectal), anemia (hemoglobin < 105 g/L,
iron deficiency anemia and thalassemia were excluded),
leukopenia (white blood cell count < 4  109/L), lympho-
penia (lymphocyte count < 109/L), neutropenia (absolute
neutrophil count < 1.5  109/L), thrombocytopenia
(platelet count <130  109/L), bandemia (band cells > 7%),
elevated C-reactive protein (CRP > 100 mg/L), hypona-
tremia (sodium < 130 mEq/L), hypocalcemia
(calcium < 7 mg/L), metabolic acidosis (pH < 7.0, bicar-
bonate levels < 24 mM and an anion gap > 16 mM).
Disseminated intravascular coagulopathy (DIC) was defined
as prolongation of the prothrombin, partial thromboplastin,
and thrombin times, as well as elevated fibrinogen degra-
dation products (D-dimers).5 Sepsis was defined as systemic
inflammatory response syndrome plus either cardiovascular
organ dysfunction or acute respiratory distress syndrome.5
2.3. Statistical analysis
Multiple logistic regression was used to identify the risk
factors for mortality by using SPSS for Windows, (SPSS Inc.,
Chicago, IL, USA) and p < 0.05 was considered significant.
The construction of the prognostic model began with
univariate assessment of the association of each charac-
teristic by estimation of OR and the corresponding 95% CIs
for the fatal and control groups. The regression coefficients
of the derived multivariate model were used to construct
the prediction rule. Multivariate logistic regression
modeling was applied to select those variables that were
associated with fatal CAP, with p <0.05 as a criterion for
entry.
3. Results
A total of 21 patients died of CAP during the study period.
Ten (48%) were boys, and 11 (52%) were girls. The average
age was 31 months (range, 1 month to 9 years). Twelve
patients (57%) were younger than 2 years; two patients
(10%) were aged 2e5 years; seven patients (33%) were older
than 5 years (Figure 1). All of the patients were admitted to
the pediatric intensive care unit either at the time of
admission (15 patients) or one day later (6 patients).
Figure 1 Age distribution of 21 patients.
24 L.-J. Wang et alVentilators, inotropic agents, and second- or third- gener-
ation antibiotics were administered for all the patients.
The average duration from admission to death was 5.2 days
(range, 4 hours to 19 days). Five patients (24%) died within
24 hours; four of them had underlying diseases [two
neuromuscular disease, one VACTER association (vertebral
abnormalities, anal atresia, ventricular septal defect,
tracheal anomalies, esophageal atresia, renal and radial
abnormalities), and one Down syndrome patient with
ventricular septal defect]. Eight patients (38%) died within
72 hours of admission. The number of CAP cases signifi-
cantly increased during the spring (March to May) compared
to other seasons (Figure 2). Fifteen patients died between
September 1992 and August 1998. Five patients died
between September 1998 and August 2004. Only one
patient died between September 2004 and August 2010
(Figure 2).
The pathogens for the CAP in our study patients are
shown in Table 1. In the fatal CAP, Gram-negative bacilli
(33.3%, in 7 patients, including four Pseudomonas aerugi-
nosa, one Salmonella Group D1, one Escherichia coli, and
one Gram-negative bacillus found on the smear of pleural
effusion but failed to culture either in pleural effusion or
blood) were the most frequently identified pathogen.
M. pneumoniae was identified in six patients (28.6%), fol-
lowed by Streptococcus pneumoniae in 2 patients (9.5%):
one was Serotype 19A; the other patient was not sent for
identification because serotyping was not available beforeFigure 2 Community-acquired pneumonia fatalities by
season and year.1996. Among these 15 patients, four patients had mixed
infections: M. pneumoniae and Streptococcus pneumoniae
(n Z 2), M. pneumoniae and P. aeruginosa (n Z 1), and
M. pneumoniae and an unknown Gram-negative bacillus
(n Z 1). Ten patients (28.6%) did not have the identified
pathogens; nine of these patients had underlying diseases.
The pathogens of 63 age-matched controlled CAP hospi-
talized patientswere identified in 46 patients (73%),whereas
17 (37%) patients were with unknown pathogens. The two
most frequently identified pathogens were S. pneumoniae in
24 patients (38%), andM. pneumoniae in 12 (19%). Among the
24 S. pneumoniae-infected patients, only two had blood
culture grown. Serotype 14 was identified in one patient
while, for the other, the subculture failed to grow and
subsequently could not be sent for identification. Gram-
negative bacilli were found in three patients, two P. aeru-
ginosa andonePertussis.Gram-positive bacilli werecultured
in three patients, one group A streptococcus bacterium, one
Streptococcus mitis and one Staphylococcus epidermidis.
Eight patients were infectedwith viruses (12.6%): sevenwith
respiratory syncytial virus and one with adenovirus. Three
patients had Chlamydia infection. Among these 53 patients,
seven patients had mixed infections: two S. pneumoniae
coinfected with M. pneumoniae, two S. pneumoniae coin-
fected with Respiratory syncytial virus, one S. pneumoniae
coinfectedwith S.mitis, oneM.pneumoniae coinfectedwith
group A streptococcus bacterium, and one M. pneumoniae
coinfected with Chlamydia. Univariate analysis showed that
Gram-negative bacilli [odds ratio (OR) Z 15.25; 95% confi-
dence interval (CI) Z 2.86e81.45; p Z 0.001]) was a risk
factor associated with mortality. S. pneumoniae was asso-
ciated inversely with fatal CAP (OR Z 0.17; 95%
CIZ 2.86e81.45; pZ 0.001).
The clinical characteristics according to etiology are
shown in Table 2. Young age and male gender were not
prognostic factors for fatal CAP. Dyspnea was present in all
fatal CAP patients. More than 90% of both fatal and survival
patients had fever. Nine patients (43%) had gastrointestinal
symptoms, including abdominal pain or vomiting. Eleven
patients (52%) presented with sepsis, and four patients
(19%) developed meningitis. One-third of the patients (33%)
developed DIC. More than half had anemia (52%). Leuko-
penia and lymphopenia were significantly observed (62%).
Thrombocytopenia was noted in more than one-third (8
patients, 38%) of the patients. Fifteen (71%) had bandemia.
Hyponatremia and hypocalcemia were noted in 38% and 43%
of patients, respectively. Metabolic acidosis occurred in
eight patients (38%). Two-thirds of the patients (14
patients, 67%) had underlying diseases, including neuro-
muscular diseases (6 patients), syndromic diseases (5
patients) and congenital heart diseases (3 patients).
Congenital heart disease was either a ventricular septal
defect or an atrial septal defect. Syndromic diseases
included one VACTER association, two with Down
syndrome, and two with Pierre Robin syndrome. Neuro-
muscular diseases include two spinal muscular atrophy, two
cerebral palsy, and two progressive muscular dystrophy.
Among the clinical characteristics, fatal CAP was associ-
ated with initial presentations of anemia, leukopenia, lym-
phopenia, neutropenia, thrombocytopenia, bandemia,
hyponatremia, sepsis, meningitis, metabolic acidosis, DIC,
andunderlying congenital diseases. Leukocytosis (ORZ 0.33;
Table 1 Pathogens of community-acquired pneumonia.
Pathogens Fatal (n Z 21) Survival (n Z 63) OR 95% CI p
M. pneumoniae 6 (28.6%) 24 (38.0%) 1.70 0.55e5.30 0.360
S. pneumoniae 2 (9.5%) 12 (19.0%) 0.17 0.28e0.84 0.025*
GNB 7 (33.3%) 3 (4.8%) 15.25 2.86e81.45 0.001*
GPB 0 3 (4.8%) 4.53 0.00 1.000
Multiple pathogens 4 (19.0%) 7 (11%) 1.41 0.39e5.17 0.600
Virus 0 8 (12.6%) 4.22 0.00 0.990
Chlamydia 0 3 (4.8%) 4.53 0.00 1.000
Unknown 10 (47.6%) 17 (27.0%) 1.58 0.58e4.29 0.370
*p < 0.05.
CI Z confidence interval; GNB Z Gram-negative bacilli; GPB Z Gram-positive bacilli; M. pneumoniae Z Mycoplasma pneumoniae;
OR Z odds ratio; S. pneumoniae Z Streptococcus pneumoniae.
Fatal community-acquired pneumonia: 18 years of study 2595% CIZ 0.12e0.93; pZ 0.04) was associated reversely with
the survival CAP; it was not a risk factor for fatal CAP. In
multivariate logistic regression analysis, metabolic acidosis
(ORZ 8.50; 95%CIZ 2.82e25.60;p< 0.001)wasaprognostic
risk factor for fatality (Table 3).4. Discussion
In our data as well as that of another study,3 clinical
response during the first 2e3 days of treatment appears to
predict outcome. Therefore; patients with underlyingTable 2 Clinical features of fatal and survival groups.
Characteristics Fatal (n Z 21) Survival (n
Age (months) 36 34
2 years 12 36
2e5 years 2 6
>5 years 7 21
Sex (M:F) 10:11 37:26
Fever 19 (90%) 59 (94%)
Hypothermia 2 (10%) 0
Dyspnea 21 (100%) 11 (17%)
GI symptoms 9 (43%) 35 (56%)
Anemia 11 (52%) 18 (29%)
Leukocytosis 7 (33%) 38 (60%)
Leukopenia 13 (62%) 11 (17%)
Lymphopenia 13 (62%) 11 (17%)
Neutropenia 3 (14%) 2 (3%)
Thrombocytopenia 8 (38%) 1 (2%)
Bandemia 15 (71%) 17 (22%)
CRP (>100 mg/L) 5 (24%) 21 (33%)
Hyponatremia 8 (38%) 3 (5%)
Hypocalcemia 9 (43%) 0
Pleural effusion 7 (33%) 27 (43%)
Sepsis 11 (52%) 9 (14%)
Meningitis 4 (19%) 3 (5%)
Metabolic acidosis 8 (38%) 2 (2%)
DIC 7 (33%) 2 (2%)
Underlying diseases 14 (67%) 12 (19%)
*p < 0.05.
CIZ confidence interval; CRPZ C-reactive protein; DICZ dissemina
ratio.diseases need to receive more medical attention especially
during the first 2e3 days.
Among the 3308 patients with CAP, 21 patients died.
Two-thirds of the fatalities occurred in patients younger
than 5 years, and the majority (12 patients, 85.7%) were
younger than 2 years. A seasonal trend toward high CAP
mortality in the spring was observed in our data. Wu et al
reported a similar finding in his paper on hospitalized
children with pneumonia from 1997 to 2004 in Taiwan.6 The
vaccination program should be heavily emphasized
between winter and spring for the children of preschool
age, especially those younger than 2 years.Z 63) OR 95% CI p
1.57 0.58e4.22 0.380
1.00 0.18e5.63 1.000
1.00 0.34e2.93 1.000
1.57 0.58e4.22 0.380
0.64 0.11e3.80 0.630
2.10 0.00 1.000
1.21 0.00 0.990
0.60 0.22e1.63 0.320
2.75 0.99e7.59 0.050*
0.33 0.12e0.93 0.040*
7.68 2.57e22.9 <0.001*
7.68 2.57e22.9 <0.001*
9.53 1.69e53.8 0.010*
38.20 4.39e331.0 0.001*
6.77 2.26e20.3 0.001*
0.63 0.20e1.94 0.420
12.31 2.87e52.8 0.001*
3.32 0.00 0.990
0.67 0.24e1.88 0.440
6.60 2.18e20.0 0.001*
4.71 0.96e23.1 0.050*
18.80 3.57e98.8 0.001*
15.30 2.89e81.4 0.001*
8.50 2.82e25.6 <0.001*
ted intravascular coagulopathy; GIZ gastrointestinal; ORZ odds
Table 3 Multivariate analysis of risk factors.
Characteristic Exp (B) 95% CI p
Anemia 0.60 0.48e7.42 0.690
Leukopenia 4.76 0.02e18.29 0.390
Thrombocytopenia 28.66 0.92e897.83 0.060
Bandemia 1.24 0.25e241.92 0.910
Hyponatremia 8.42 0.39e182.12 0.170
Sepsis 0.67 0.07e6.31 0.730
Meningitis 11.91 0.26e140.36 0.270
Metabolic acidosis 60.79 3.59e1027.53 0.004*
DIC 8.08 0.49e132.25 0.140
Congenital diseases 7.23 0.72e72.29 0.090
*p < 0.05.
CI Z confidence interval; DIC Z disseminated intravascular
coagulopathy.
26 L.-J. Wang et alThe identified pathogens were seven Gram-negative
bacilli (33.3%) and six M. pneumoniae (28.6%) in fatal
CAP. The majority of M. pneumoniae infections (4 patients)
were complicated with other pathogens, either with
S. pneumoniae (n Z 2), P. aeruginosa (n Z 1), or unknown
Gram-negative bacillus (nZ 1). Five patients infected with
M. pneumoniae were older than 2 years; one was an 11-
month-old patient. In a Japanese study, the most preva-
lent pediatric age for M. pneumoniae admission to the
hospital was 1 year old.7 Therefore, M. pneumoniae should
be considered for children as young as 1 year in addition to
school-age children. M. pneumoniae accounts for 7e40% of
all community-acquired pneumonias among children aged
3e15 years. Coinfections with S. pneumoniae (30%) are
common, but fatal M. pneumoniae infections are rare.8 In
our study, among these six M. pneumoniae patients were
two previously healthy patients coinfected with S. pneu-
moniae resulting in meningoencephalitis and sepsis; one
patient coinfected with Pseudomonas aeruginosa had
underlined cerebral palsy and seizure disorder. The other
patient coinfected with unknown Gram-negative bacillus
was a previous premature birth at 34 weeks. Of the other
two isolated M. pneumoniae-infected patients, one had
spinal muscular atrophy, the other had large atrial septal
defect (ASD, 1.6 cm) with moderate left-to-right shunt and
pulmonary hypertension. Although the mortality rate of M.
pneumoniae is low, with either the complications of
Streptococcus pneumoniae or Gram-negative pathogens,
along with underlined congenital diseases or prematurity,
an immune-compromised status may cause death.
Children younger than 1 year were particularly vulner-
able to Gram-negative bacilli; four of the seven children in
this study who died from Gram-negative bacilli infection
were less than 1 year old. These four children (three with P.
aeruginosa and one with Salmonella Group D1) had under-
lying neuromuscular diseases. Early administration of anti-
biotics covering Gram-negative as well as Gram-positive
bacilli in this age group is crucial, especially in those who
have a compromised pulmonary function. The poor prog-
nostic pathogen of fatal CAP was associated with Gram-
negative bacilli (OR Z 15.25; 95% CI Z 2.86e81.45;
p Z 0.001). A new evidence-based guideline on pediatric
pneumonia was published by the Pediatric InfectiousDiseases Society and the Infectious Diseases Society of
America on August 31, 2011.9
A total of 3308 CAP patients were admitted to our
pediatric ward during these 18 years. Among these, 912
patients were admitted from September 1992 to August
1998, 997 patients during August 1998 to August 2004, and
1399 patients from September 2004 to August 2010. The
overall in-hospital mortality was 0.63% during 18 years. The
year-period mortality rate was 1.6% from September 1992
to August 1998, 0.5% from September 1998 to August 2004,
and 0.07% from September 2004 to August 2010. Admission
of patients with pneumonia has increased, but fatal pneu-
monia has dramatically decreased (Figure 2). This might be
attributed to more intensive treatments and the use of
pneumococcal vaccines. The 23-valent pneumococcal
polysaccharide vaccine was introduced to Taiwan in 1999,
and the 7-valent pneumococcal conjugate vaccine was
available in 2005. These vaccines may have contributed to
the trend of decreasing fatalities shown in Figure 2. The
only patient who died in the last 6 years was a previously
healthy 2-year-old boy. S. pneumoniae 19A was cultured
from his blood. This serotype has been reported with
increasing frequency worldwide and has the highest
potential for causing invasive pneumococcal disease.10
Further investigation is needed to interpret that not just
the S. pneumoniae itself but the specific serotype, for
example, 19A, is associated with a poor prognostic
outcome. The coverage of 19A pneumococcal 13-valent
vaccine was introduced to Taiwan in April 2011. Continued
survey for the invasive novel serotypes and development of
vaccines with expanded coverage will be critical for further
prevention of pneumococcal infections.
In this study the presence of anemia, leukopenia, lym-
phopenia, neutropenia, thrombocytopenia, bandemia,
hyponatremia, metabolic acidosis, sepsis, meningitis, DIC
or underlying diseases were poor prognostic factors in fatal
CAP compared to the control group. In contrast, elevated
CRP, leukocytosis, and pleural effusion were not associated
with a poor outcome. Hyponatremia is associated with the
severity of CAP and is an independent predictor of both
myocardial infarction and mortality in middle-aged and
elderly community subjects.11,12 Hyponatremia is likely the
result of the syndrome of inappropriate antidiuretic
hormone secretion, which is a well-known complication of
pneumonia. In multivariate logistic regression analysis,
metabolic acidosis (OR Z 8.50; 95% CI Z 2.82e25.60;
p < 0.001) was a prognostic risk factor for fatality. There-
fore, blood gas test has to be included in the blood sampling
on admission. Leukocytosis was independently associated
with survivals in CAP, which implied an immune-competent
status, was not a poor prognostic factor.
In conclusion, a febrile child presenting with respiratory
distress or gastrointestinal symptoms shouldbeevaluated for
severe bacterial pneumonia. Pneumococcal pneumonia
should be considered when treating CAP. In addition, M.
pneumoniae as a culprit should also be suspected for both
preschool and school-aged patients. Antibiotics covering
Gram-negative bacilli also are recommended. Children with
underlying diseases associated with immune-compromised
status require more aggressive medical attention. If labora-
tory data show signs of any predictors of mortality (anemia,
leukopenia, lymphopenia, neutropenia, thrombocytopenia,
Fatal community-acquired pneumonia: 18 years of study 27bandemia, hyponatremia, metabolic acidosis, sepsis,
meningitis, DIC, and underlying diseases), the patients need
to be admitted and aggressive treatment should be started
immediately. Earlier recognition of high-risk patients and
aggressive intervention mayminimize subsequent mortality.
Childrenwhohavenot substantially improvedwithin 48hours
after the start of antibiotics should be re-examined, and
treatment should be modified if indicated. For treatment of
CAP in the future, the outcomes that can be standardized,
measured, and compared will allow us to establish bench-
marks for the care of children with CAP.
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